Avadel Pharmaceuticals (AVDL) Liabilities and Shareholders Equity: 2009-2022
Historic Liabilities and Shareholders Equity for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Sep 2022 value amounting to $145.8 million.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity fell 44.81% to $145.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $772.1 million, marking a year-over-year decrease of 32.94%. This contributed to the annual value of $247.3 million for FY2021, which is 20.66% down from last year.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity amounted to $145.8 million in Q3 2022, which was down 7.71% from $157.9 million recorded in Q2 2022.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $351.9 million during Q1 2018, with a 5-year trough of $145.8 million in Q3 2022.
- In the last 3 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $264.1 million in 2021 and averaged $254.6 million.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 50.66% in 2019, then spiked by 110.17% in 2020.
- Over the past 5 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $190.3 million in 2018, then fell by 20.42% to $151.4 million in 2019, then surged by 105.79% to $311.6 million in 2020, then declined by 20.66% to $247.3 million in 2021, then tumbled by 44.81% to $145.8 million in 2022.
- Its Liabilities and Shareholders Equity stands at $145.8 million for Q3 2022, versus $157.9 million for Q2 2022 and $221.1 million for Q1 2022.